PRTA logo

Prothena (PRTA) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Ireland

IPO:

18 December 2012

Indexes:

Not included

Description:

Prothena is a biotechnology company focused on developing treatments for neurodegenerative diseases, such as Alzheimer's and Parkinson's. They use innovative science to create therapies that target protein misfolding, aiming to improve patients' lives and address significant medical needs in these areas.

Events Calendar

Earnings

Next earnings date:

Feb 14, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Feb 15, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

20 Dec '24 HC Wainwright & Co.
Buy
20 Dec '24 Chardan Capital
Buy
19 Dec '24 B of A Securities
Neutral
13 Nov '24 HC Wainwright & Co.
Buy
01 Oct '24 HC Wainwright & Co.
Buy
01 Oct '24 B of A Securities
Neutral
30 Sept '24 Cantor Fitzgerald
Overweight
14 Aug '24 Oppenheimer
Outperform
12 Aug '24 Cantor Fitzgerald
Overweight
09 Aug '24 RBC Capital
Sector Perform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Prothena Announces Board of Directors Update
Prothena Announces Board of Directors Update
Prothena Announces Board of Directors Update
PRTA
businesswire.com30 December 2024

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena announced that Oleg Nodelman will step down from Prothena's Board of Directors to create time to focus on existing and new endeavors.

Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?
Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?
Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?
PRTA
zacks.com12 December 2024

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?

Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus
Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus
Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus
PRTA
zacks.com13 November 2024

PRTA posts a narrower-than-expected loss in the third quarter. The company also reports encouraging pipeline progress for the quarter.

Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates
Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates
Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates
PRTA
zacks.com12 November 2024

Prothena (PRTA) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.18. This compares to earnings of $0.38 per share a year ago.

Prothena (PRTA) Upgraded to Buy: What Does It Mean for the Stock?
Prothena (PRTA) Upgraded to Buy: What Does It Mean for the Stock?
Prothena (PRTA) Upgraded to Buy: What Does It Mean for the Stock?
PRTA
zacks.com29 October 2024

Prothena (PRTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength?
Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength?
Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength?
PRTA
zacks.com29 October 2024

Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Prothena Announces Leadership Team Updates
Prothena Announces Leadership Team Updates
Prothena Announces Leadership Team Updates
PRTA
businesswire.com27 September 2024

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that Chad Swanson, Ph.D., has been appointed Chief Development Officer.

What Makes Prothena (PRTA) a New Buy Stock
What Makes Prothena (PRTA) a New Buy Stock
What Makes Prothena (PRTA) a New Buy Stock
PRTA
zacks.com19 August 2024

Prothena (PRTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues
Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues
Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues
PRTA
zacks.com09 August 2024

Prothena (PRTA) records impressive second-quarter earnings as the top line benefits from a $80-million payment from collaboration partner BMY.

Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?
Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?
Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?
PRTA
zacks.com24 June 2024

Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

FAQ

  • What is the primary business of Prothena?
  • What is the ticker symbol for Prothena?
  • Does Prothena pay dividends?
  • What sector is Prothena in?
  • What industry is Prothena in?
  • What country is Prothena based in?
  • When did Prothena go public?
  • Is Prothena in the S&P 500?
  • Is Prothena in the NASDAQ 100?
  • Is Prothena in the Dow Jones?
  • When was Prothena's last earnings report?
  • When does Prothena report earnings?
  • Should I buy Prothena stock now?

What is the primary business of Prothena?

Prothena is a biotechnology company focused on developing treatments for neurodegenerative diseases, such as Alzheimer's and Parkinson's. They use innovative science to create therapies that target protein misfolding, aiming to improve patients' lives and address significant medical needs in these areas.

What is the ticker symbol for Prothena?

The ticker symbol for Prothena is NASDAQ:PRTA

Does Prothena pay dividends?

No, Prothena does not pay dividends

What sector is Prothena in?

Prothena is in the Healthcare sector

What industry is Prothena in?

Prothena is in the Biotechnology industry

What country is Prothena based in?

Prothena is headquartered in Ireland

When did Prothena go public?

Prothena's initial public offering (IPO) was on 18 December 2012

Is Prothena in the S&P 500?

No, Prothena is not included in the S&P 500 index

Is Prothena in the NASDAQ 100?

No, Prothena is not included in the NASDAQ 100 index

Is Prothena in the Dow Jones?

No, Prothena is not included in the Dow Jones index

When was Prothena's last earnings report?

Prothena's most recent earnings report was on 12 November 2024

When does Prothena report earnings?

The next expected earnings date for Prothena is 14 February 2025

Should I buy Prothena stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions